CollPlant Biotechnologies (CLGN) investors approve EGM proposal
Rhea-AI Filing Summary
CollPlant Biotechnologies Ltd. reported that it held an Extraordinary General Meeting of Shareholders on July 29, 2026. Shareholders approved the proposal presented at the meeting, which had been described in the company’s Notice of Extraordinary General Meeting of Shareholders dated July 7, 2026.
The report is incorporated by reference into CollPlant’s existing Registration Statements on Form S-8 and Form F-3, becoming part of those registration statements from the submission date, unless later superseded.
Positive
- None.
Negative
- None.
Key Figures
Extraordinary General Meeting date: July 29, 2026
Notice of Meeting date: July 7, 2026
2 metrics
Extraordinary General Meeting date
July 29, 2026
Date the Extraordinary General Meeting of Shareholders was held
Notice of Meeting date
July 7, 2026
Date of the Notice of Extraordinary General Meeting describing the proposal
Key Terms
Form 6-K, foreign private issuer, Extraordinary General Meeting of Shareholders, Registration Statements on Form S-8, +1 more
5 terms
Form 6-K regulatory
"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Registration Statements on Form S-8 regulatory
"incorporated by reference into the registrant’s Registration Statements on Form S-8"
Registration Statements on Form F-3 regulatory
"incorporated by reference into the registrant’s Registration Statements on Form F-3"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did CollPlant Biotechnologies (CLGN) report in its July 2026 Form 6-K?
CollPlant Biotechnologies reported that it held an Extraordinary General Meeting of Shareholders on July 29, 2026, where shareholders approved the proposal presented. The approved proposal had been described in a Notice of Extraordinary General Meeting dated July 7, 2026.
When was CollPlant Biotechnologies' (CLGN) Extraordinary General Meeting held?
The Extraordinary General Meeting of Shareholders was held on July 29, 2026. This meeting followed a Notice of Extraordinary General Meeting distributed on July 7, 2026, which described the proposal later approved by the company’s shareholders at the meeting.
How does this CollPlant Biotechnologies (CLGN) report relate to its registration statements?
The report is incorporated by reference into CollPlant’s Registration Statements on Form S-8 and Form F-3. This means the information from the report becomes part of those registration statements from the submission date, unless later superseded by other reports.
Which SEC forms are referenced in CollPlant Biotechnologies' (CLGN) July 2026 report?
The company references existing Registration Statements on Form S-8 and Form F-3. The July 2026 report is incorporated by reference into multiple S-8 registration statements and several F-3 registration statements identified by their respective file numbers.